339 related articles for article (PubMed ID: 31015190)
1. Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis.
Albeituni S; Verbist KC; Tedrick PE; Tillman H; Picarsic J; Bassett R; Nichols KE
Blood; 2019 Jul; 134(2):147-159. PubMed ID: 31015190
[TBL] [Abstract][Full Text] [Related]
2. Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis.
Das R; Guan P; Sprague L; Verbist K; Tedrick P; An QA; Cheng C; Kurachi M; Levine R; Wherry EJ; Canna SW; Behrens EM; Nichols KE
Blood; 2016 Mar; 127(13):1666-75. PubMed ID: 26825707
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of itacitinib, fedratinib, and ruxolitinib in mouse models of hemophagocytic lymphohistiocytosis.
Keenan C; Albeituni S; Oak N; Stroh A; Tillman HS; Wang Y; Freeman BB; Alemán-Arteaga S; Meyer LK; Woods R; Verbist KC; Zhou Y; Cheng C; Nichols KE
Blood; 2024 Jun; 143(23):2386-2400. PubMed ID: 38446698
[TBL] [Abstract][Full Text] [Related]
4. Cellular and transcriptional impacts of Janus kinase and/or IFN-gamma inhibition in a mouse model of primary hemophagocytic lymphohistiocytosis.
Albeituni S; Oak N; Tillman HS; Stroh A; Keenan C; Bloom M; Nichols KE
Front Immunol; 2023; 14():1137037. PubMed ID: 37228616
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice.
Maschalidi S; Sepulveda FE; Garrigue A; Fischer A; de Saint Basile G
Blood; 2016 Jul; 128(1):60-71. PubMed ID: 27222478
[TBL] [Abstract][Full Text] [Related]
6. IFN-γ and CD25 drive distinct pathologic features during hemophagocytic lymphohistiocytosis.
Humblet-Baron S; Franckaert D; Dooley J; Ailal F; Bousfiha A; Deswarte C; Oleaga-Quintas C; Casanova JL; Bustamante J; Liston A
J Allergy Clin Immunol; 2019 Jun; 143(6):2215-2226.e7. PubMed ID: 30578871
[TBL] [Abstract][Full Text] [Related]
7. JAK inhibition for murine HLH requires complete blockade of IFN-γ signaling and is limited by toxicity of JAK2 inhibition.
Chaturvedi V; Lakes N; Tran M; Castillo N; Jordan MB
Blood; 2021 Sep; 138(12):1034-1039. PubMed ID: 34232994
[TBL] [Abstract][Full Text] [Related]
8. Ruxolitinib-loaded cytokine nanosponge alleviated the cytokine storm and dampened macrophage overactivation for the treatment of hemophagocytic lymphohistiocytosis.
Wang H; Wang Y; Liu H; Li X; Sun C; Pang Z; Zhang B; Hu Y
Int J Pharm; 2024 May; 657():124127. PubMed ID: 38621611
[TBL] [Abstract][Full Text] [Related]
9. Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis.
Keenan C; Nichols KE; Albeituni S
Front Immunol; 2021; 12():614704. PubMed ID: 33664745
[TBL] [Abstract][Full Text] [Related]
10. IL-2 consumption by highly activated CD8 T cells induces regulatory T-cell dysfunction in patients with hemophagocytic lymphohistiocytosis.
Humblet-Baron S; Franckaert D; Dooley J; Bornschein S; Cauwe B; Schönefeldt S; Bossuyt X; Matthys P; Baron F; Wouters C; Liston A
J Allergy Clin Immunol; 2016 Jul; 138(1):200-209.e8. PubMed ID: 26947179
[TBL] [Abstract][Full Text] [Related]
11. JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation.
Meyer LK; Verbist KC; Albeituni S; Scull BP; Bassett RC; Stroh AN; Tillman H; Allen CE; Hermiston ML; Nichols KE
Blood; 2020 Aug; 136(6):657-668. PubMed ID: 32530039
[TBL] [Abstract][Full Text] [Related]
12. ST2 contributes to T-cell hyperactivation and fatal hemophagocytic lymphohistiocytosis in mice.
Rood JE; Rao S; Paessler M; Kreiger PA; Chu N; Stelekati E; Wherry EJ; Behrens EM
Blood; 2016 Jan; 127(4):426-35. PubMed ID: 26518437
[TBL] [Abstract][Full Text] [Related]
13. Trigger-dependent differences determine therapeutic outcome in murine primary hemophagocytic lymphohistiocytosis.
Gather R; Aichele P; Goos N; Rohr J; Pircher H; Kögl T; Zeiser R; Hengel H; Schmitt-Gräff A; Weaver C; Ehl S
Eur J Immunol; 2020 Nov; 50(11):1770-1782. PubMed ID: 32419134
[TBL] [Abstract][Full Text] [Related]
14. Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis.
Johnson TS; Terrell CE; Millen SH; Katz JD; Hildeman DA; Jordan MB
J Immunol; 2014 Jan; 192(1):84-91. PubMed ID: 24259502
[TBL] [Abstract][Full Text] [Related]
15. Rapamycin does not control hemophagocytic lymphohistiocytosis in LCMV-infected perforin-deficient mice.
Rothman JA; Das R; Teachey DT; Paessler ME; Nichols KE
Pediatr Blood Cancer; 2011 Dec; 57(7):1239-43. PubMed ID: 21681935
[TBL] [Abstract][Full Text] [Related]
16. Genetic Deficiency of Interferon-γ Reveals Interferon-γ-Independent Manifestations of Murine Hemophagocytic Lymphohistiocytosis.
Burn TN; Weaver L; Rood JE; Chu N; Bodansky A; Kreiger PA; Behrens EM
Arthritis Rheumatol; 2020 Feb; 72(2):335-347. PubMed ID: 31400073
[TBL] [Abstract][Full Text] [Related]
17. Hemophagocytic lymphohistiocytosis in syntaxin-11-deficient mice: T-cell exhaustion limits fatal disease.
Kögl T; Müller J; Jessen B; Schmitt-Graeff A; Janka G; Ehl S; zur Stadt U; Aichele P
Blood; 2013 Jan; 121(4):604-13. PubMed ID: 23190531
[TBL] [Abstract][Full Text] [Related]
18. Combined IFN-γ and JAK inhibition to treat hemophagocytic lymphohistiocytosis in mice.
Joly JA; Vallée A; Bourdin B; Bourbonnais S; Patey N; Gaboury L; Théorêt Y; Decaluwe H
J Allergy Clin Immunol; 2023 Jan; 151(1):247-259.e7. PubMed ID: 35973477
[TBL] [Abstract][Full Text] [Related]
19. A Griscelli syndrome type 2 murine model of hemophagocytic lymphohistiocytosis (HLH).
Pachlopnik Schmid J; Ho CH; Diana J; Pivert G; Lehuen A; Geissmann F; Fischer A; de Saint Basile G
Eur J Immunol; 2008 Nov; 38(11):3219-25. PubMed ID: 18991284
[TBL] [Abstract][Full Text] [Related]
20. Mouse Cytomegalovirus Infection in BALB/c Mice Resembles Virus-Associated Secondary Hemophagocytic Lymphohistiocytosis and Shows a Pathogenesis Distinct from Primary Hemophagocytic Lymphohistiocytosis.
Brisse E; Imbrechts M; Put K; Avau A; Mitera T; Berghmans N; Rutgeerts O; Waer M; Ninivaggi M; Kelchtermans H; Boon L; Snoeck R; Wouters CH; Andrei G; Matthys P
J Immunol; 2016 Apr; 196(7):3124-34. PubMed ID: 26903481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
